Citations

Clear

439 citation(s) found for "Stone, M".

A multi-institutional review of endovenous thermal ablation of the saphenous vein finds male sex and use of anticoagulation are predictors of long-term failure
Erben, Young , Vasquez, Isabel, Li, Yupeng , Gloviczki, Péter , Kalra, Manju , Martino, Randall R. De , Bjarnason, Haraldur , Neisen, Melissa , Moore, January , Rocha-Franco, Joao A. Da, Sanchez-Valenzuela, Maria C., Frey, G. , Toskich, Beau , Devcic, Zlatko , Farres, Houssam , Oldenburg, W. A., Gomez-Perez, Jessica, Yarbrough, Justin, Adalia, Michael, Stone, William M., Meltzer, Andrew J., Hakaim, Albert G., Oderich, Gustavo, De Martino, Randall R, Neisen, Melissa J, Moore, January F, Da Rocha-Franco, Joao A, Oldenburg, Warren A, Yarbrough, Justin R, Stone, William, Bjarnason, Haraldur , Oderich, Gustavo S. , Gloviczki, Péter

Mayo Clinic

Phlebology: The Journal of Venous Disease | November 12, 2020 | Volume: 36 | Issue: 4 | Pages: 283-289

10.1177/0268355520972923 | PMID 33176592 Get It

Background To review long-term outcomes and saphenous vein (SV) occlusion rate after endovenous ablation (EVA) for symptomatic varicose veins. Methods A review of our EVA database (1998–2018) with at least 3-years of clinical and sonographic follow-up. The primary end point was SV closure rate. Results 542 limbs were evaluated. 358 limbs had radiofrequency and 323 limbs had laser ablations; 542 great saphenous veins (GSV), 106 small saphenous veins (SSV) and 33 anterior accessory saphenous veins (AASV) were treated. Follow-up was 5.6 ± 2.3 years; 508 (74.6%) veins were occluded, 53 (7.8%) partially occluded and 120 (17.6%) were patent. On multivariable Cox regression analysis, male sex (HR 1.6, 95% CI [0.46–018], p = 0.012) and use anticoagulation (HR 2.0, 95% CI [0.69–0.34], p = 0.044) were predictors of long-term failure. On Kaplan-Meier curve, we had an 86.3% occlusion rate. Conclusion Our experience revealed a 5-year closure rate of 86.3%. Ablations have satisfactory occlusion rate.
Subsequent urinary stone events are predicted by the magnitude of urinary oxalate excretion in enteric hyperoxaluria
D’Costa, Matthew R. , Kausz, Annamaria T., Carroll, Kevin J., Ingimarsson, Johann P. , Mara, Kristin C. , Mehta, Ramila A. , Enders, Felicity T, D'Costa, Matthew , Mara, Kristin C , Enders, Felicity , Lieske, John C.

Mayo Clinic

Nephrology Dialysis Transplantation | October 14, 2020 | Volume: 36 | Issue: 12 | Pages: 2208-2215

10.1093/ndt/gfaa281 | PMID 33367720 Get It

Abstract Data directly demonstrating the relationship between urinary oxalate (UOx) excretion and stone events in those with enteric hyperoxaluria (EH) are limited. Therefore, we assessed the relationship between UOx excretion and risk of kidney stone events in a retrospective population-based EH cohort. In all, 297 patients from Olmsted County, Minnesota were identified with EH based upon having a 24-h UOx ≥40 mg/24 h preceded by a diagnosis or procedure associated with malabsorption. Diagnostic codes and urologic procedures consistent with kidney stones during follow-up after baseline UOx were considered a new stone event. Logistic regression and accelerated failure time modeling were performed as a function of UOx excretion to predict the probability of new stone event and the annual rate of stone events, respectively, with adjustment for urine calcium and citrate. Mean ± standard deviation age was 51.4 ± 11.4 years and 68% were female. Median (interquartile range) UOx was 55.4 (46.6–73.0) mg/24 h and 81 patients had one or more stone event during a median follow-up time of 4.9 (2.8–7.8) years. Higher UOx was associated with a higher probability of developing a stone event (P < 0.01) and predicted an increased annual risk of kidney stones (P = 0.001). Estimates derived from these analyses suggest that a 20% decrease in UOx is associated with 25% reduction in the annual odds of a future stone event. Thus, these data demonstrate an association between baseline UOx and stone events in EH patients and highlight the potential benefit of strategies to reduce UOx in this patient group. Background Data directly demonstrating the relationship between urinary oxalate (UOx) excretion and stone events in those with enteric hyperoxaluria (EH) are limited. Methods We assessed the relationship between UOx excretion and risk of kidney stone events in a retrospective population-based EH cohort. In all, 297 patients from Olmsted County, Minnesota were identified with EH based upon having a 24-h UOx ≥40 mg/24 h preceded by a diagnosis or procedure associated with malabsorption. Diagnostic codes and urologic procedures consistent with kidney stones during follow-up after baseline UOx were considered a new stone event. Logistic regression and accelerated failure time modeling were performed as a function of UOx excretion to predict the probability of new stone event and the annual rate of stone events, respectively, with adjustment for urine calcium and citrate. Results Mean ± SD age was 51.4 ± 11.4 years and 68% were female. Median (interquartile range) UOx was 55.4 (46.6–73.0) mg/24 h and 81 patients had ≥1 stone event during a median follow-up time of 4.9 (2.8–7.8) years. Higher UOx was associated with a higher probability of developing a stone event (P < 0.01) and predicted an increased annual risk of kidney stones (P = 0.001). Estimates derived from these analyses suggest that a 20% decrease in UOx is associated with 25% reduction in the annual odds of a future stone event. Conclusions These data demonstrate an association between baseline UOx and stone events in EH patients and highlight the potential benefit of strategies to reduce UOx in this patient group.
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial
Voso, Maria Teresa , Larson, Richard A. , Marcucci, Guido , Prior, Thomas W., Krauter, Jürgen, Heuser, Michael , Nomdedéu, Josep , Geyer, Susan M. , Wei, Andrew H. , Sierra, Jorge , Sanz, Miguel Á. , Brandwein, Joseph , Witte, Theo M. de, Niederwieser, Dietger , Appelbaum, Frederick R. , Medeiros, Bruno C. , Tallman, Martin S. , Schlenk, Richard F. , Ganser, Arnold , Cheng, Yuan, Chen, Yin-Miao, Pallaud, Céline , Du, Ling, Piciocchi, Alfonso , Ehninger, Gerhard , Byrd, John C. , Thiede, Christian , Döhner, Konstanze , Stone, Richard M. , Bloomfield, Clara D. , Byrd, John C. , Larson, Richard A , Wei, Andrew H , Jones, Dan M. , Lavorgna, Serena , Walker, Alison , Jansen, Joop H. , Amadori, Sergio , Cheng, Yuan, Döhner, Hartmut , Lo‐Coco, Francesco , Voso, Maria Teresa , Byrd, John C

Mayo Clinic

Blood Advances | October 13, 2020 | Volume: 4 | Issue: 19 | Pages: 4945-4954

10.1182/bloodadvances.2020002904 | PMID 33049054 Get It

Abstract The results from the RATIFY trial (ClinicalTrials.gov: NCT00651261; CALGB 10603) showed that midostaurin combined with standard chemotherapy significantly improved outcomes in patients with FMS-like tyrosine kinase 3 (FLT3)–mutated acute myeloid leukemia (AML), compared with placebo. In this post hoc subgroup analysis from the trial, we evaluated the impact of midostaurin in 163 patients with FLT3-tyrosine kinase domain (TKD) mutations. At a median follow-up of 60.7 months (95% CI, 55.0-70.8), the 5-year event-free survival (EFS) rate was significantly higher in patients treated with midostaurin than in those treated with placebo (45.2% vs 30.1%; P = .044). A trend toward improved disease-free survival was also observed with midostaurin (67.3% vs 53.4%; P = .089), whereas overall survival (OS) was similar in the 2 groups. Patients with AML and NPM1mut/FLT3-TKDmut or core binding factor (CBF)–rearranged/FLT3-TKDmut genotypes had significantly prolonged OS with or without censoring at hematopoietic cell transplantation (HCT), compared with NPM1WT/CBF-negative AMLs. The multivariable model for OS and EFS adjusted for allogeneic HCT in first complete remission as a time-dependent covariable, revealed NPM1 mutations and CBF rearrangements as significant favorable factors. These data show that NPM1 mutations or CBF rearrangements identify favorable prognostic groups in patients with FLT3-TKD AMLs, independent of other factors, also in the context of midostaurin treatment.
One Year Outcomes From a Prospective Multicenter Investigation Device Trial of a Novel Conformal Mesh Interbody Fusion Device
Driver, Joseph , Krag, Martin H. , Bydon, Mohamad , Nunley, Pierce D. , Lavoie, Stéphane, Stone, Marcus B., Chi, John H., Huang, Kevin T. , Lavoie, Stephane, Lu, Yi , Chi, John H.

Mayo Clinic

Spine | September 28, 2020 | Volume: 46 | Issue: 2 | Pages: E126-E132

10.1097/brs.0000000000003710 | PMID 32991515 Get It

Study Design. A prospective multicenter investigational device exempt trial is underway evaluating a novel conformable mesh interbody fusion device in subjects undergoing single-level fusion for degenerative disc disease. Patients meeting inclusion and exclusion criteria were offered enrollment. There is no comparative group in this study. Objective. Establish the short and long-term safety and effectiveness of a novel conformable mesh interbody fusion device in subjects undergoing single-level fusion for degenerative disc disease unresponsive to conservative care. Summary of Background Data. Transforaminal lumbar interbody fusion remains a critical procedure for patients with degenerative lumbar disc disease. Increasingly minimally invasive techniques have been proposed to minimize muscle dissection and tissue damage with the goal of minimizing pain and length of stay. Methods. One hundred two subjects were enrolled across 10 sites. Ninety nine subjects remained available for follow-up at 12-months. Physical evaluations/imaging were performed serially through 12-months. Validated assessment tools included 100 mm visual analogue scale (VAS) for pain, Oswestry Disability Index (ODI) for function, and computerized tomography scan for fusion. Independent committees were used to identify adverse events and for assessment of radiographic fusion. Results. Reductions in low back pain (LBP)/leg pain and improvements in functional status occur early and are maintained through 12-month follow-up. Mean VAS-LBP change from baseline to 6-weeks post-op (–46 mm) continued to improve through 12 months (–51 mm). Similar trends were observed for leg pain. Mean ODI change from baseline to 6 weeks post-op (–17) was almost doubled by 12 months (–32). Fusion rates at 12-months are high (98%). No device-related serious adverse events have occurred. Conclusion. 12-month outcomes demonstrated excellent patient compliance and positive outcomes for pain, function, fusion, and device safety. Clinical improvements were observed by 6-weeks post-op and appear durable up to 1 year later. A novel mesh interbody device may provide an alternative means of interbody fusion that reduces connective tissue disruption. Level of Evidence: 3
Transcatheter Mitral Valve Replacement After Surgical Repair or Replacement
Simonato, Matheus , Ribeiro, Henrique Barbosa , Webb, John G. , Backer, Ole De , Villablanca, Pedro, Rihal, Charanjit S. , Eleid, Mackram F. , Kempfert, Jörg , Unbehaun, Axel , Erlebach, Magdalena , Casselman, Filip , Saia, Francesco , Ubben, Timm , Meincke, Felix , Napodano, Massimo, Codner, Pablo , Schöfer, Joachim, Pelletier, Marc , Cheung, Anson , Shuvy, Mony , Palma, José Honório , Duncan, Alison , Sinning, Jan-Malte, Arbel, Yaron , Weger, Arend de , Eltchaninoff, Hélène, Hemery, Thibault, Tchétché, Didier , Dumonteil, Nicolas, Rodés‐Cabau, Josep , Kim, Won-Keun, Spargias, Konstantinos, Kourkoveli, Panagiota, Ben‐Yehuda, Ori , Barbanti, Marco , Fiorina, Claudia , Thukkani, Arun K., Jones, Noah, Presbitero, Patrizia , Petronio, Anna Sonia , Champagnac, Didier , Rudolph, Tanja K. , Iadanza, Alessandro , Nombela‐Franco, Luis , Bonaros, Nikolaos , Kass, Malek , Amabile, Nicolas , Messina, Antonio , Andreas, Martin , Welsh, Robert C. , Schoels, Wolfgang , Hellig, Farrel, Windecker, Stephan , Stortecky, Stefan , Maisano, Francesco , Stone, Gregg W. , Dvir, Danny , Rihal, Charanjit, Eleid, Mackram, Nombela-Franco, Luis , Windecker, Stephan , Maisano, Francesco , De Backer, Ole , Whisenant, Brian K. , Kornowski, Ran , Guerrero, Mayra , Wijeysundera, Harindra C. , Søndergaard, Lars , Rihal, Charanjit S. , Adam, Matti , Montorfano, Matteo , Ancona, Marco , Gaia, Diego Felipe , Hildick-Smith, David , Veulemans, Verena , Sinning, Jan‐Malte, Testa, Luca , Landes, Uri , Kim, Won-Keun, Teles, Rui Campante , Mackensen, G. Burkhard , Allali, Abdelhakim , Bleiziffer, Sabine , Salizzoni, Stefano , Agrifoglio, Marco , Bruschi, Giuseppe , Chhatriwalla, Adnan K , Hirji, Sameer

Mayo Clinic

Circulation | September 25, 2020 | Volume: 143 | Issue: 2 | Pages: 104-116

10.1161/circulationaha.120.049088 | PMID 32975133 Get It

Background: Mitral valve-in-valve (ViV) and valve-in-ring (ViR) are alternatives to surgical reoperation in patients with recurrent mitral valve failure after previous surgical valve repair or replacement. Our aim was to perform a large-scale analysis examining midterm outcomes after mitral ViV and ViR. Methods: Patients undergoing mitral ViV and ViR were enrolled in the Valve-in-Valve International Data Registry. Cases were performed between March 2006 and March 2020. Clinical endpoints are reported according to the Mitral Valve Academic Research Consortium (MVARC) definitions. Significant residual mitral stenosis (MS) was defined as mean gradient ≥10 mm Hg and significant residual mitral regurgitation (MR) as ≥ moderate. Results: A total of 1079 patients (857 ViV, 222 ViR; mean age 73.5±12.5 years; 40.8% male) from 90 centers were included. Median STS-PROM score 8.6%; median clinical follow-up 492 days (interquartile range, 76–996); median echocardiographic follow-up for patients that survived 1 year was 772.5 days (interquartile range, 510–1211.75). Four-year Kaplan-Meier survival rate was 62.5% in ViV versus 49.5% for ViR ( P <0.001). Mean gradient across the mitral valve postprocedure was 5.7±2.8 mm Hg (≥5 mm Hg; 61.4% of patients). Significant residual MS occurred in 8.2% of the ViV and 12.0% of the ViR patients ( P =0.09). Significant residual MR was more common in ViR patients (16.6% versus 3.1%; P <0.001) and was associated with lower survival at 4 years (35.1% versus 61.6%; P =0.02). The rates of Mitral Valve Academic Research Consortium–defined device success were low for both procedures (39.4% total; 32.0% ViR versus 41.3% ViV; P =0.01), mostly related to having postprocedural mean gradient ≥5 mm Hg. Correlates for residual MS were smaller true internal diameter, younger age, and larger body mass index. The only correlate for residual MR was ViR. Significant residual MS (subhazard ratio, 4.67; 95% CI, 1.74–12.56; P =0.002) and significant residual MR (subhazard ratio, 7.88; 95% CI, 2.88–21.53; P <0.001) were both independently associated with repeat mitral valve replacement. Conclusions: Significant residual MS and/or MR were not infrequent after mitral ViV and ViR procedures and were both associated with a need for repeat valve replacement. Strategies to improve postprocedural hemodynamics in mitral ViV and ViR should be further explored.
Occipital-Cervical Fusion and Ventral Decompression in the Surgical Management of Chiari-1 Malformation and Syringomyelia: Analysis of Data From the Park-Reeves Syringomyelia Research Consortium
CreveCoeur, Travis S. , Yahanda, Alexander T. , Maher, Cormac O. , Johnson, Gabrielle W. , Ackerman, Laurie L. , Adelson, P. David , Albert, Gregory W. , Aldana, Phillipp R, Alden, Tord D. , Anderson, Richard C. E. , Baird, Lissa , Bauer, David F. , Bierbrauer, Karin S. , Brockmeyer, Douglas L. , Chern, Joshua J. , Couture, Daniel E., Daniels, David, Dauser, Robert C., Durham, Susan, Ellenbogen, Richard G. , Eskandari, Ramin , Fuchs, Herbert E., George, Timothy M., Greene, Stephanie , Gross, Naina L. , Guillaume, Daniel, Hankinson, Todd C. , Heuer, Gregory G. , Iantosca, Mark, Iskandar, Bermans J. , Jackson, Eric M. , Jea, Andrew, Johnston, James M. , Keating, Robert F., Kelly, Michael P. , Khan, Nickalus R. , Krieger, Mark D., Leonard, Jeffrey R. , Mangano, Francesco T. , Mapstone, Timothy B., McComb, J. Gordon , Muhlbauer, Michael S., Oakes, W. Jerry, Olavarria, Greg, O’Neill, Brent R., Park, Tae Sung, Ragheb, John , Shannon, Chevis N. , Smith, Jodi L. , Stone, Scellig , Strahle, Jennifer M. , Tamber, Mandeep S. , Torner, James C., Tuite, Gerald F. , Wait, Scott D. , Wellons, John C. , Whitehead, William E. , Limbrick, David D. , Torner, James C. , Kelly, Michael P , Yahanda, Alexander T , Ahmed, Raheel , Aldana, Phillip R., Grant, Gerald A. , Graupman, Patrick C. , Greenfield, Jeffrey P. , Guillaume, Daniel J, Haller, Gabe , Menezes, Arnold H. , Selden, Nathan R. W. , Shah, Manish N. , Shimony, Joshua S. , Limbrick, David D.

Mayo Clinic

Neurosurgery | September 22, 2020 | Volume: 88 | Issue: 2 | Pages: 332-341

10.1093/neuros/nyaa460 | PMID 33313928 Get It

Abstract BACKGROUND Occipital-cervical fusion (OCF) and ventral decompression (VD) may be used in the treatment of pediatric Chiari-1 malformation (CM-1) with syringomyelia (SM) as adjuncts to posterior fossa decompression (PFD) for complex craniovertebral junction pathology. OBJECTIVE To examine factors influencing the use of OCF and OCF/VD in a multicenter cohort of pediatric CM-1 and SM subjects treated with PFD. METHODS The Park-Reeves Syringomyelia Research Consortium registry was used to examine 637 subjects with cerebellar tonsillar ectopia ≥ 5 mm, syrinx diameter ≥ 3 mm, and at least 1 yr of follow-up after their index PFD. Comparisons were made between subjects who received PFD alone and those with PFD + OCF or PFD + OCF/VD. RESULTS All 637 patients underwent PFD, 505 (79.2%) with and 132 (20.8%) without duraplasty. A total of 12 subjects went on to have OCF at some point in their management (PFD + OCF), whereas 4 had OCF and VD (PFD + OCF/VD). Of those with complete data, a history of platybasia (3/10, P = .011), Klippel-Feil (2/10, P = .015), and basilar invagination (3/12, P < .001) were increased within the OCF group, whereas only basilar invagination (1/4, P < .001) was increased in the OCF/VD group. Clivo-axial angle (CXA) was significantly lower for both OCF (128.8 ± 15.3°, P = .008) and OCF/VD (115.0 ± 11.6°, P = .025) groups when compared to PFD-only group (145.3 ± 12.7°). pB-C2 did not differ among groups. CONCLUSION Although PFD alone is adequate for treating the vast majority of CM-1/SM patients, OCF or OCF/VD may be occasionally utilized. Cranial base and spine pathologies and CXA may provide insight into the need for OCF and/or OCF/VD.
Can CT-Based Stone Impaction Markers Augment the Predictive Ability of Spontaneous Stone Passage?
Kachroo, Naveen , Jain, Rajat , Maskal, Sara M. , Alshara, Luay, Armanyous, Sherif, Milk, Jason, Kahn, Leonard B., Monga, Manoj , Sivalingam, Sri , Kahn, Leonard, Jain, Rajat

Mayo Clinic

Journal of Endourology | September 4, 2020 | Volume: 35 | Issue: 4 | Pages: 429-435

10.1089/end.2020.0645 | PMID 32883100 Get It

Introduction: A number of clinical and radiological predictors of either stone impaction or ureteral stone passage (SP) have been proposed. We aimed at identifying the key predictors of successful SP by using readily available CT-based tools/measurements. Methods: Patients presenting to the emergency department from February 2017 to February 2018 with an acute unilateral ureteral stone confirmed on non-contrast CT and managed conservatively were followed for SP. Patients with renal impairment, sepsis or requiring emergent intervention were excluded. Patients were followed at 1 month to confirm SP (stone collection/repeat imaging) or failure of passage. The CT variables analyzed included: Stone factors [location, size, volume, HU density (HUD)], impaction factors [ureteral HUD above and below the stone, maximal ureteral wall thickness (UWT) at the stone site, contralateral UWT, and ureteral diameter above and below the stone]. Binary logistic regression analysis was performed to identify predictors of SP. Results: Forty-nine patients met study inclusion criteria, of whom 32 (65.3%) passed the stone without further intervention. Patients with successful passage were more likely to have smaller, lower volume and less dense stones located in the distal ureter ( p < 0.01). Lower ureteral HUD below the stone, lower maximal UWT, and lower ureteral diameter above the stone were associated with successful passage ( p < 0.01). On multivariable logistic regression analysis, only maximal UWT at the stone site was a significant independent predictor of SP outcome ( p = 0.01). Youden's criterion identified 2.3 mm as the optimal UWT cut-off point, which will accurately predict SP with 82.4% sensitivity and 87.5% specificity. Conclusions: Maximal UWT at the stone site was the most significant predictor of successful passage in acute unilateral ureteral stones, with an optimal cut-off point of 2.3 mm. Further prospective studies are needed to accurately predict spontaneous SP.
Excretion of urine extracellular vesicles bearing markers of activated immune cells and calcium/phosphorus physiology differ between calcium kidney stone formers and non-stone formers
Jayachandran, Muthuvel, Wang, Stanley , Lieske, John C. , Lieske, John C , Zhang, Jiqing , Kumar, Sanjay , Jayachandran, Muthuvel , Wilson, Elena M.

Mayo Clinic

No container title available | September 3, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-64903/v1 Get It

Abstract Backgrounds: Previous studies have demonstrated that excretion of urinary extracellular vesicles (EVs) from different nephron segments differs between kidney stone formers and non-stone formers (NSFs), and could reflect pathogenic mechanisms of urinary stone disease. In this study we quantified selected populations of specific urinary EVs carrying protein markers of immune cells and calcium/phosphorus physiology in calcium stone formers (CSFs) compared to non-stone formers (NSFs). Methods Incident CSFs (n = 24) and age- and sex- matched NSFs (n = 21) were studied. Clinical data were abstracted and biobanked cell-free urine samples were used to quantify specific urinary EV populations. EVs carrying proteins related to renal calcium/phosphorus physiology (phosphorus transporters (PiT1 and PiT2), Klotho, and fibroblast growth factor 23 (FGF23)); markers associated with EV generation (anoctamin-4 (ANO4) and Huntington interacting protein 1 (HIP1)), and markers shed from activated immune cells were quantified by standardized and published method of digital flow cytometry. Results The urine pH of CSFs was lower than NSFs (P < 0.05), whereas urine excretion of calcium, phosphorus, and calcium oxalate and uric acid supersaturation (SS) were significantly higher in CSFs compared to NSFs (P < 0.05). Urinary excretion of EVs with markers of total leukocytes (CD45), neutrophils (CD15), macrophages (CD68), Klotho, FGF23, PiT1, PiT2, and ANO4 were each markedly lower in CSFs than NSFs (P < 0.05) whereas excretion of those with markers of monocytes (CD14), T-Lymphocytes (CD3), B-Lymphocytes (CD19), plasma cells (CD138 plus CD319 positive ) were not different between the groups. Urinary excretion of EVs expressing PiT1 and PiT2 negatively (P < 0.05) correlated with urinary phosphorus excretion whereas excretion of EVs expressing FGF23 correlated negatively (P < 0.05) with both urinary calcium and phosphorus excretion. Conclusions Urinary excretion of EVs derived from specific types of activated immune cells and EVs with proteins related to calcium/phosphorus regulation were different between CSFs and NSFs. Thus, further validation of these and other populations of urinary EVs could identify biomarkers that elucidate novel pathogenic mechanisms of calcium stone formation in specific subsets of patients.
Endarterectomy for Iliac Occlusive Disease during Kidney Transplantation: A Multicenter Experience
Sorrells, William S., Mao, Shennen A. , Taner, Timuçin , Farres, Houssam , Davila, Victor , Money, Samuel R., Stone, William M., Al-Khasawneh, Mohammad, Rocha-Franco, Joao A. Da Rocha Da, Oldenburg, W. Andrew, Hakaim, Albert G., Da Rocha-Franco, Joao A Da Rocha, Oldenburg, Warner A, Taner, C. Burcin , Mao, Shennen A , Jadlowiec, Caroline C. , Davila, Victor J. , Rocha-Franco, Joao A. Da, Oderich, Gustavo S. , Erben, Young

Mayo Clinic

International Journal of Angiology | August 30, 2020 | Volume: 30 | Issue: 02 | Pages: 091-097

10.1055/s-0040-1714752 | PMID 34054266 Get It

AbstractLittle is known about the surgical challenges and outcomes of kidney transplantation (KT) in the face of severe iliac occlusive disease (IOD). We aim to examine our institution's experience and outcomes compared with all KT patients. Retrospective review of our multi-institutional transplant database identified patients with IOD requiring vascular surgery involvement for iliac artery endarterectomy at time of KT from 2000 to 2018. Clinical data, imaging studies, and surgical outcomes of 22 consecutive patients were reviewed. Our primary end-point was allograft survival. Secondary end-points included mortality and perioperative complications. A total of 6,757 KT were performed at our three sites (Florida, Arizona, and Minnesota); there were 22 (0.32%) patients receiving a KT with concomitant IOD requiring iliac artery endarterectomy. Mean patient age was 61.45 ± 7 years. There were 13 (59.1%) male patients. The most common etiology of renal failure was diabetic nephropathy in 10 patients (45.5%) followed by a combination of hypertensive/diabetic nephropathy in five patients (22.7%), and hypertensive nephrosclerosis in three patients (13.6%). The majority (n = 16, 72.7%) of patients received renal allografts from deceased donors and six (27.3%) were recipients from living donors. Mean time from dialysis to transplantation was 2.9 ± 2.9 years. Mean follow-up was 3.5 ± 2.5 years. Mean length of hospital stay was 6.3 ± 4.3 days (range: 3–18 days). Graft loss within 90 days occurred in two (9.1%) patients, one due to renal vein thrombosis and another due to acute tubular necrosis. Overall allograft survival was 90.1% at 1-year and 86.4% at 3-year follow-up. Overall mortality occurred in 6 (27.3%) patients. Perioperative complications (Clavien-Dindo Grade 2–4) occurred in 13 (59.1%) patients, including 10 (45.5%) with acute blood loss anemia requiring transfusion, 2 (9.1%) reoperations for hematoma evacuation, 1 (4.5%) ischemic colitis requiring total abdominal colectomy, and 1 (4.5%) renal vein thrombosis requiring nephrectomy. IOD patients selected for KT are not common and although challenging, they have similar outcomes to our standard KT patients. The 1- and 3-year allograft survivals were 90.1 and 86.4% versus 96.0 and 90.3% in the general KT patient population. With these excellent outcomes, we recommend expanding the criteria for KT to include patients with IOD with prior vascular surgery consultation to prevent progression of IOD or prevention of wait list removal in select patients who are otherwise good candidates for KT.
Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis
Owczarczyk, Kasia , Cascino, Matthew D., Holweg, Cécile , Tew, Gaik W. , Ortmann, Ward , Behrens, Timothy W. , Langford, Carol A. , Clair, E. William St. , Merkel, Peter A. , Kallenberg, Cees G. M., Lim, Noha , Stone, John H., Brunetta, Paul , Prunotto, Marco , Merkel, Peter A , Schindler, Thomas Hellmut , Spiera, Robert , Seo, Philip , Specks, Ulrich

Mayo Clinic

JCI Insight | August 25, 2020 | Volume: 5 | Issue: 18 | Pages: No page available

10.1172/jci.insight.136180 | PMID 32841219 Get It

BACKGROUND Baseline expression of FCRL5 , a marker of naive and memory B cells, was shown to predict response to rituximab (RTX) in rheumatoid arthritis. This study investigated baseline expression of FCRL5 as a potential biomarker of clinical response to RTX in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). METHODS A previously validated quantitative PCR–based (qPCR-based) platform was used to assess FCRL5 expression in patients with GPA/MPA (RAVE trial, NCT00104299). RESULTS Baseline FCRL5 expression was significantly higher in patients achieving complete remission (CR) at 6, 12, and 18 months, independent of other clinical and serological variables, among those randomized to RTX but not cyclophosphamide-azathioprine (CYC/AZA). Patients with baseline FCRL5 expression ≥ 0.01 expression units (termed FCRL5 hi ) exhibited significantly higher CR rates at 6, 12, and 18 months as compared with FCRL5 lo subjects (84% versus 57% [ P = 0.016], 68% versus 40% [ P = 0.02], and 68% versus 29% [ P = 0.0009], respectively). CONCLUSION Our data taken together suggest that FCRL5 is a biomarker of B cell lineage associated with increased achievement and maintenance of complete remission among patients treated with RTX and warrant further investigation in a prospective manner. FUNDING The analysis for this study was funded by Genentech Inc.